Impact of donor type on transplant outcomes in patients with MF

The estimated 3-year overall survival (OS) rates were 68.8%, 59%, 61.3%, and 55.2% with MSD, Haplo, MUD, and MMUD, respectively (p = 0.03). 

Multivariable analysis demonstrated that allo-HSCT with MSD was associated with improved OS in the first 3 months post-transplant (Haplo: hazard ratio [HR], 5.79; 95% confidence interval [CI], 2.54–13.20; MUD: HR, 4.48; 95% CI, 2.25–8.92; MMUD: HR, 5.24; 95% CI, 1.49–18.42; p < 0.001). There was no significant OS difference between the three non-MSD donor types in the first 3 months, and no difference between all donor types beyond 3 months post transplant.

The use of MSD was associated with a lower incidence of graft failure than Haplo (HR, 6.11; 95% CI, 2.98–12.54; p <0.001) and MUD (HR, 2.33; 95% CI, 1.20–4.51; p = 0.01), and lower non-relapse mortality (NRM) than Haplo (HR, 1.71; 95% CI, 1.09–2.68), MUD (HR, 1.58; 95% CI, 1.14–2.18), and MMUD (HR, 1.71; 05% CI, 0.98–2.97; p = 0.03). The NRM rates were similar between patients who received allo-HSCT with Haplo, MUD, and MMUD.

Relapse and disease-free survival were similar between all donor types. Additionally, in the subset of patients who underwent allo-HSCT within 24 months of diagnosis (n = 481), OS was not associated with donor type.